Sign In
Section Navigation
Common TitleTANGO
Official Title A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Phase Phase III
ClinicalTrials.gov NCT03446573
Treatments
Dolutegravir-Lamivudine
Dolutegravir-Lamivudine Dovato

Dolutegravir-Lamivudine

Tradename:DovatoOther Names:DTG-3TCClass:Single-Tablet Regimens
Categories Switch/SimplificationDual Therapy
Funding
IndustryViiV Healthcare
References
  • van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71:1920-9.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.